Figure 3.

Ipilimumab treatment increases peripheral TCR diversity but does not correlate with clinical outcomes. PBMC samples from 16 patients, both at baseline and after 2 cycles of ipilimumab treatment, were sorted into CD4⁺ and CD8⁺ T cells and subjected to survey-level next-generation high-throughput sequencing of the TCR Vβ CDR3 region. Patients were chosen to represent 3 subgroups: (i) patients who achieved MCB (n = 5); (ii) patients who progressed/did not achieve MCB (nonresponders, n = 7); and (iii) patients who developed IRAEs to ipilimumab treatment and had to be taken off study (toxicity, n = 4). A-B, Clonality, Gini coefficient, and top 20 T-cell clones for CD4⁺ and CD8⁺ T cells were calculated as described in the Supplementary Appendix. Data, mean + SD. Changes in clonality (A) and Gini coefficient (B) improved after 2 cycles but did not correlate with clinical response to treatment and achieving MCB.